ACM
SLNO

Altium Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Altium Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250,000
Closed -$11.2M – 60
2024
Q4 		$11.2M Buy
250,000
+37,091
+17% +$1.92M 3.19% 10
2024
Q3 		$10.7M Hold
212,909
– – 3.16% 8
2024
Q2 		$8.69M Buy
212,909
+60,000
+39% +$2.54M 3.54% 10
2024
Q1 		$6.54M Buy
152,909
+48,000
+46% +$2.17M 2.59% 16
2023
Q4 		$4.22M Buy
104,909
+57,828
+123% +$1.65M 2.87% 14
2023
Q3 		$1.39M Buy
+47,081
New +$285K 0.72% 31

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altium Capital Management's SLNO Position: Q1 2025 in Review

Altium Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2025, closing a stake of 250,000 shares — an estimated $11.2M sold.

Altium Capital Management first reported a position in SLNO in Q3 2023 and held it in 6 quarters. The position peaked at $11.2M in Q4 2024. 217 funds tracked by Wall St. Rank hold SLNO as of Q1 2025.

  • Altium Capital Management reported no remaining Soleno Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 250,000 Soleno Therapeutics shares in Q1 2025, an estimated $11.2M.
  • Altium Capital Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 6 quarters.
  • Altium Capital Management's Soleno Therapeutics position peaked at $11.2M in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.